{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoNrZnJ8LDA","lastupdate":"2024-09-11T00:00:00.000Z","update_date":"2024-09-11T00:00:00.000Z","lastModified":"Sep 14, 2024","active":1,"confidence_score":90,"confidence_score_reason":"video or image, markets, not claimed","urlname":"ayala-pharmaceuticals","minimal_profile":null,"status":"Acquired","fullstatus":"Acquired by Advaxis on Jan, 2023","acquired":1,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$3qXch2p2aevQd2Qmpo1H1HSUsFRdIUDzmD1E4Kauj00mt7A5Pc2bl9","name":"Ayala Pharmaceuticals","oneliner":"Targeted Therapies for People with Rare Cancers","registrar":"515748697","website":"https://ayalapharma.com","careerspage":"https://ayalapharma.com/careers","founded_month":1,"founded_year":2017,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/AyalaPharma","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/18445059","instagram":""},"social":["https://www.linkedin.com/company/18445059","https://twitter.com/AyalaPharma"],"flattenedsociallinks":"https://www.linkedin.com/company/18445059|https://twitter.com/AyalaPharma","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":30,"patent":1,"raised":102000000,"stage":"Acquired","public_stage":"Acquired","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Ayala Pharmaceuticals is a clinical-stage precision oncology company dedicated to developing and commercializing potential small molecule therapeutics for patients suffering from rare and aggressive cancers, especially in genetically defined patient populations.\r\n\r\nAyalas product candidates, AL101 and AL102, are designed to target cancer by addressing the underlying key drivers of tumor growth. Both product candidates target the aberrant activation of the Notch pathway with gamma-secretase inhibitors (GSIs). By developing drugs designed to inhibit Notch pathway activation, Ayala is enabling personalized therapy for cancer patients.\r\n\r\nIn 2017, the company entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for its gamma-secretase inhibitors. Ayalas lead product, AL101, granted orphan drug designation by the FDA in 2019, has completed preclinical and phase 1 studies. A phase 2 study (ACCURACY) for AL101 in patients with adenoid cystic carcinoma bearing activated Notch mutations has been initiated.\r\n\r\nIn 2018, Ayala entered into a deal with Novartis to develop and commercialize AL102 in combination with BCMA-targeting agents in multiple myeloma. In addition, Ayala is evaluating AL102 as an inhibitor of the Notch pathway in hematologic cancers.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97283731541","country":null,"address":{"israeli":[{"id":"a8a1a8fd-dde3-4d4f-bbfa-3f8f6a782c55","city":"Rehovot","type":null,"address":"Prof. Hillel ve-Khanan Oppenheimer St 4, Rehovot, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"81bd1816-1ff3-4e31-b674-d50c84264713","city":"Wilmington","address":"1007 North Orange Street, Wilmington, DE, USA","country":"United States","placeid":null}]},"headquarter_address":null,"district":"Center District","news":[{"id":"Sp1yseyQi9VwDy4n5BhCxmwmTvxih9aIVR4tm6tTjMBIdOwidf8EzK","date":"May 8, 2024","link":"https://finance.yahoo.com/news/ayala-pharmaceuticals-files-form-15-201000021.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"deregistration","company":"Ayala Pharmaceuticals","layoffs":"","summary":"Ayala Pharmaceuticals, a clinical-stage oncology company, announced that it has filed a Form 15 with the SEC to deregister its common stock and suspend its reporting obligations under the Exchange Act. This means the company will no longer be required to file periodic reports such as Forms 10-K, 10-Q, and 8-K. The deregistration is expected to be effective within 90 days of filing. This move indicates that Ayala Pharmaceuticals will no longer be a public reporting company.","partners":"","customers":"","investors":"","confidence":10,"key_topics":["deregistration","SEC","oncology","reporting","Form 15"],"date_of_event":"May 09, 2024","valuation_amount":"","impact_on_company":"growth-negative","investment_amount":"","structured_issues":["Public Trading"],"acquisition_amount":"","structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"0afI1rfsiwZ6k8zU1C6yT39vlFUuU9bRLtGrt2pgLI9EydIGH8W2LB","news_summary":"Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"UAB5rd6Aq4TVhaUtkdn91yJUmdZWehIUImNyrBJHPi8uNOycMs7iM7","date":"Oct 18, 2023","link":"https://finance.yahoo.com/news/ayala-pharmaceuticals-announces-closing-merger-120000486.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"merger","company":"Ayala Pharmaceuticals","layoffs":null,"summary":"Ayala Pharmaceuticals, a clinical-stage oncology company, announced the completion of its merger with Biosight, Ltd. The combined entity will continue to operate under the name Ayala Pharmaceuticals, Inc., and its shares will trade on the OTCQX under the ticker symbol ADXS. The merger expands Ayalas product pipeline, adding aspacytarabine (BST-236), a novel antimetabolite in clinical development for AML. The companys primary focus remains on completing the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. The existing senior management team of Ayala will lead the combined company, with some new appointments from Biosight. The merger is expected to bring synergies and growth opportunities.","partners":null,"customers":null,"investors":[],"confidence":10,"key_topics":["merger","oncology","clinical trials","management","product pipeline"],"date_of_event":"2023-10-19","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"niJG0s4qpyyHcABadNMkVkIidi9BryiHSy7wqmJO6XevpyYSfqia7P","news_summary":"Ayala Pharmaceuticals Announces Closing of Merger with Biosight","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"WhCyHP7Ak9CBDO64ShddOKn8o9roD6ZvDH7WIcVvM7v3qeQz0eDNT0","date":"Jul 27, 2023","link":"https://www.globenewswire.com/news-release/2023/07/27/2712158/0/en/Ayala-Pharmaceuticals-and-Biosight-Enter-into-Definitive-Merger-Agreement.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Merger, Oncology, Pharmaceuticals","company":"Ayala Pharmaceuticals, Inc., Biosight Ltd.","layoffs":"Not mentioned","summary":"Ayala Pharmaceuticals and Biosight Ltd. have announced a definitive merger agreement. The combined company will operate under the name Ayala Pharmaceuticals and will continue to trade on the OTCQX under Ayala’s current ticker symbol. The merger will add a clinical stage oncology asset to Ayala’s portfolio. The combined company will work to advance a portfolio of oncology assets, with a primary focus on Ayala’s AL102 and Biosight’s Aspacytarabine (BST-236). The merger is expected to close prior to the end of the third quarter of 2023.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":"Merger, Oncology, Pharmaceuticals, Management, Stock Transaction","date_of_event":"July 27, 2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":"Acquired-by, Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Acquired-by, Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"Hslk70HL0uWBnwRq0Iu2jwb62yp7ZHOq28EPRk5AES6tyxCLvcUaeH","news_summary":"Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d4lNcXLSnpiRKvcw7Ptrk0li8C19r5N3WWXzG09a5hQyWbo7nEQTVg","date":"Feb 10, 2023","link":"https://www.globenewswire.com/news-release/2023/02/10/2605831/0/en/Ayala-Pharmaceuticals-Reports-Financial-Results-For-the-Fiscal-Year-Ended-October-31-2022.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Merger, Financial Results, Clinical Trials","company":"Ayala Pharmaceuticals, Inc.","layoffs":"N/A","summary":"Ayala Pharmaceuticals, previously known as Advaxis Inc., has announced its financial results for the fiscal year ending October 31, 2022. The company closed its merger in January 2023 and is now focused on the development and commercialization of AL102 for the treatment of desmoid tumors. The company reported revenues of $250,000 for the fiscal year 2022, compared to $3.2 million for the fiscal year 2021. The net loss for the fiscal year ended October 31, 2022, was approximately $14.4 million.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Merger","Financial Results","Clinical Trials","Cancer Treatment","FDA Approval"],"date_of_event":"February 10, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Acquired-by","Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Acquired-by  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"DE38WqwfLSfIbfxwVSkXonXYnaDZlx1l14JPnoc2i3Vkhd87crB1ou","news_summary":"Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LZBPsQYmD09Ot1nB86VnT6IaqdIhnhEKTd5WKMk2cPkVwi1dgZlcwb","date":"Jan 19, 2023","link":"https://www.globenewswire.com/news-release/2023/01/19/2591928/0/en/Advaxis-and-Ayala-Pharmaceuticals-Complete-Merger.html#:~:textJanuary%2019%2C%202023%2009%3A37,%7C%20Source%3A%20Advaxis%2C%20Inc.","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"merger","company":"Advaxis, Inc.","layoffs":null,"summary":"Advaxis, Inc. has completed a merger with Ayala Pharmaceuticals, Inc. The merged company will operate under the name Ayala Pharmaceuticals and will focus on the development and commercialization of Ayalas lead program AL102 for the treatment of desmoid tumors. Advaxis is seeking to uplist to Nasdaq in the near future. The management and board of directors of the merged company have been announced. Ayala Pharmaceuticals is primarily focused on developing and commercializing small molecule therapeutics for rare tumors and aggressive cancers. Their lead candidates under development are AL102 and ADXS-504. AL102 has received Fast Track Designation from the U.S. FDA and is currently in the Phase 3 portion of a pivotal study for patients with desmoid tumors.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["merger","oncology","immunotherapies","clinical-stage","small molecule therapeutics"],"date_of_event":"January 19, 2023","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"iyYK8Na8C9KDeCFD0ijwEjGlcsNkurd4BpebV7kdzZK8279X293nCX","news_summary":"Advaxis and Ayala Pharmaceuticals Complete Merger","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Vr3c2ps7XL7fbf0sVcwlyGWpv85W8h1vrxRwhhXD02HxJHrAX895Zz","date":"Nov 16, 2022","link":"https://www.globenewswire.com/news-release/2022/11/16/2557161/0/en/Ayala-Pharmaceuticals-Announces-First-Patient-Dosed-with-AL102-in-Phase-3-Segment-of-RINGSIDE-Trial-in-Desmoid-Tumors.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Clinical Trials, Oncology","company":"Ayala Pharmaceuticals, Inc.","layoffs":"N/A","summary":"Ayala Pharmaceuticals, a clinical-stage oncology company, has announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI). The Phase 3 segment of RINGSIDE is a double-blind, multi-center trial enrolling up to 156 patients with progressive disease. Positive interim data from Part A, the Phase 2 segment of RINGSIDE were presented at ESMO in September 2022. AL102 received Fast Track designation from the U.S. FDA granted in September 2022 for the treatment of progressing desmoid tumors.","partners":"N/A","customers":"Patients with desmoid tumors","investors":"N/A","confidence":9,"key_topics":["Clinical Trials","Oncology","Desmoid Tumors","AL102","RINGSIDE Study"],"date_of_event":"Nov. 16, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"e3k1MlqAqb73gs482IKAeTuAcbOeCnjzt07KE1OzcOVhvF2XjpqVKx","news_summary":"Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7VTKOKkWgkfsQ7T39P3h24Eb94iIozdLGkMRN79Pgc91gPWKBCs7Ok","date":"Oct 19, 2022","link":"https://www.globenewswire.com/news-release/2022/10/19/2537180/0/en/Ayala-Pharmaceuticals-and-Advaxis-Enter-into-Merger-Agreement.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Merger, Uplisting","company":"Ayala Pharmaceuticals, Inc. and Advaxis, Inc.","layoffs":"N/A","summary":"Ayala Pharmaceuticals and Advaxis have announced a definitive merger agreement. The merger will result in a combined company that will focus predominantly on the development and commercialization of Ayala’s lead program AL102 for the treatment of desmoid tumors and Advaxis’s candidate ADXS-504 in development for prostate cancer. Upon completion of the merger, Ayala stockholders will own approximately 62.5% of the combined company’s outstanding common stock and Advaxis stockholders will own approximately 37.5%. The combined company plans to seek uplisting to Nasdaq.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Merger","Clinical Trials","Management Changes","Nasdaq Uplisting","Share Distribution"],"date_of_event":"Oct. 19, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Acquired-by","Management Changes","Public Trading"],"acquisition_amount":"N/A","structuredIssuesShow":"#Acquired-by  #Management Changes  #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"mOli6tUkHPi10MNCqfkJGIcjdqlrrcBDWH67M8rh9HGkwZWukavTBF","news_summary":"Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d65519b4-a50a-4d2b-b99e-3a24bb168d5f","date":"May 10, 2020","link":"https://en.globes.co.il/en/article-ayala-pharmaceuticals-raises-55m-in-nasdaq-ipo-1001328011","source":"en.globes.co.il","visible":1,"analysis":{"tags":"biotech, fundraising, cancer treatment","company":"Ayala Pharmaceuticals","layoffs":null,"summary":"Israeli biotech company Ayala Pharmaceuticals has raised $55 million in a fundraising round on Nasdaq. The company is developing Notch inhibitors for aggressive cancers that are in Phase II trials. Ayala Pharmaceuticals specializes in the treatment of a certain type of cancer that presents Notch pathway mutations. The recent fundraising round was led by pharmaceuticals company Novartis, which has previously invested in Ayala and may be interested in collaborating with them in the future. The companys share price ended its first day of trading up 0.03% at $15.03, giving a market cap of $182.1 million.","partners":["Novartis"],"customers":null,"investors":["Novartis"],"confidence":9,"key_topics":["Notch inhibitors","Phase II trials","fundraising","partnerships","cancer treatment"],"date_of_event":"May 10, 2020","valuation_amount":"$182.1 million","impact_on_company":"growth-positive","investment_amount":"$55 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sZveKwGBNvWwIvgjNy5srpaZkTVY1SKZBueTNvXMtqCT4814l33ZGx","news_summary":"Ayala Pharmaceuticals raises $55m in Nasdaq IPO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8b6761f7-f818-4321-ad5d-2c4420d7a0e1","date":"May 7, 2020","link":"https://www.globenewswire.com/news-release/2020/05/07/2030078/0/en/Ayala-Pharmaceuticals-Announces-Pricing-of-Initial-Public-Offering.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"IPO, public trading","company":"Ayala Pharmaceuticals","layoffs":null,"summary":"Ayala Pharmaceuticals, a clinical-stage oncology company, has announced the pricing of its initial public offering (IPO) of common stock. The IPO consists of 3,666,667 shares of common stock at a price of $15.00 per share. The offering is expected to close on May 12, 2020, and Ayala has granted the underwriters a 30-day option to purchase additional shares. The gross proceeds of the offering are expected to be $55.0 million. Ayalas common stock will begin trading on the NASDAQ Global Market under the ticker symbol AYLA on May 8, 2020. Citigroup and Jefferies are the lead book-running managers for the offering, with Oppenheimer & Co. and Raymond James acting as co-managers.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["IPO","public offering","underwriters","stock","prospectus"],"date_of_event":"May 8, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IzHLtvozX8vwTHIs5NnwKTCtmVSSxY8ef764O53ohmFXDWkdWzIAsZ","news_summary":"Ayala Pharmaceuticals Announces Pricing of Initial Public Offering","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8bb317a2-1f07-4445-9b80-0e005dc6dc64","date":"Mar 8, 2020","link":"https://en.globes.co.il/en/article-ayala-pharma-files-for-nasdaq-ipo-1001320950","source":"en.globes.co.il","visible":1,"analysis":{"tags":"IPO","company":"Ayala Pharmaceuticals","layoffs":null,"summary":"Israeli-US cancer treatment company Ayala Pharmaceuticals has filed a draft prospectus for an IPO on Nasdaq, seeking to raise $50 million. The company has not disclosed its valuation for the IPO, but it is expected to be in the hundreds of millions of dollars. The underwriters for the IPO are Citi, Jefferies, Oppenheimer, and Raymond James. Ayala Pharmaceuticals was founded by venture capital firms IBF and aMoon, and has raised $70 million so far. The company is developing treatments for cancers involving the Notch mutation. It has received products from Bristol-Myers Squibb and has signed a licensing deal with Novartis. Ayala Pharmaceuticals posted a loss of $17 million in 2019, mainly due to research and development expenses.","partners":["Novartis"],"customers":null,"investors":["IBF","aMoon","Harel Insurance Investments and Financial Services Ltd.","SBI","Novartis"],"confidence":9,"key_topics":["cancer treatment","IPO","investors","partnerships","coronavirus"],"date_of_event":"March 8, 2020","valuation_amount":"not disclosed","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"39Ta2gWv0DGDdklaPHZfET1zWnvWpqLlxKifoCawcmEAup7oon6kQF","news_summary":"Ayala Pharma files for Nasdaq IPO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"91ecf7bc-90da-4e39-997d-dcd7f4723c83","date":"Mar 3, 2020","link":"https://www.businesswire.com/news/home/20200303005178/en/Ayala-Pharmaceuticals-Granted-U.S.-FDA-Fast-Track","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"728RXs6j95j1H4CEQ4HavIfZn6H2v3ayOgADpF1z2x1LZh6TNqLy1j","news_summary":"Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101 for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"b7c017b7-6c3f-460f-8340-913dea21c20d","date":"Jan 7, 2020","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3777246,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"IPO, cancer treatment","company":"Ayala Pharmaceuticals Inc.","layoffs":null,"summary":"Israel-based Ayala Pharmaceuticals Inc. plans to raise $100 million through a Nasdaq IPO. The company, which is valued at $400 million, is a precision oncology company developing targeted therapies for rare cancers. Ayala has tapped Citi Bank and Jefferies Group LLC to lead the IPO. It has previously raised $52.60 million in funding, with investors including Novartis International AG, Israel Biotech Fund, Harel Insurance Investments & Financial Services Ltd., and aMoon.","partners":null,"customers":null,"investors":"Novartis International AG, Israel Biotech Fund, Harel Insurance Investments & Financial Services Ltd., aMoon","confidence":9,"key_topics":["IPO","Cancer treatment","Funding","Investors","Valuation"],"date_of_event":"01.20","valuation_amount":"$400 million","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Public Trading"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Public Trading","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MxiBVcxUK2tVKNtAJAb8iRYN3CzsiDnudp6uXYWcKDrJ7sSKKk8je0","news_summary":"Ayala Pharmaceuticals Headed for Nasdaq IPO","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a3c4d59a-0006-495b-ac86-610201f88690","date":"Sep 30, 2019","link":"https://www.businesswire.com/news/home/20190930005098/en/Ayala-Pharmaceuticals-Presents-Encouraging-Preliminary-Safety-Efficacy","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"poetUrUbY4k3R2ikYU5L0U3EjMwHTwcNRMsvyYyfjAmNOAAjyCHNqQ","news_summary":"Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMO","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"19b381fe-de20-41ae-8c96-8005b9fae7b6","date":"Sep 19, 2019","link":"https://www.businesswire.com/news/home/20190919005544/en/Ayala-Pharmaceuticals-Announces-Presentation-European-Society-Medical","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Medical Conference","company":"Ayala Pharmaceuticals, Inc.","layoffs":"Not mentioned","summary":"Ayala Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that a poster will be presented at the European Society for Medical Oncology (ESMO) in Barcelona, Spain from September 27 to October 1, 2019. The poster will detail the phase 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic adenoid cystic carcinoma patients with Notch activating mutations.","partners":"Not mentioned","customers":"Not mentioned","investors":"None","confidence":9,"key_topics":"Cancer Therapy, Medical Conference, Clinical Trials","date_of_event":"September 27 to October 1, 2019","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"None","acquisition_amount":"Not mentioned","structuredIssuesShow":"#None","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"l7J6iryvITthGy9ZY0CXspqJDkGQXEaoT6t27ftlW4KOX5rw0GUsxS","news_summary":"Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"8b130112-22ae-41d1-b300-f021056dff10","date":"Sep 9, 2019","link":"https://www.fiercebiotech.com/biotech/ayala-pharma-nabs-abbvie-cancer-exec-gary-gordon-as-cmo","source":"www.fiercebiotech.com","visible":1,"analysis":{"tags":"Legal","company":"Questex LLC","layoffs":"N/A","summary":"The article discusses the terms of use and privacy policy of Questex LLC.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":8,"key_topics":["Questex LLC","Terms of use","Privacy Policy"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"N/A","investment_amount":"N/A","structured_issues":[],"acquisition_amount":"N/A","entityGrowthIconPath":"none;"},"sentiment":"N/A","analysisId":"6Ut9mpk3LwLolu3yGD5kay77ga0QYcgek46NIsCdmSCg8qPf2cfh4r","news_summary":"Ayala Pharma nabs AbbVie cancer exec Gordon as CMO","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"cfdf6016-6635-4b81-ad29-b6c76bc2d5b0","date":"Jul 8, 2019","link":"https://www.prnewswire.com/news-releases/archerdx-and-ayala-pharmaceuticals-announce-strategic-companion-diagnostic-collaboration-300880320.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"strategic collaboration, companion diagnostic tests, precision oncology","company":"ArcherDX, Inc.","layoffs":null,"summary":"ArcherDX and Ayala Pharmaceuticals have announced a strategic collaboration to develop companion diagnostic tests targeting cancers with Notch activating mutations and fusions. The partnership aims to bring biomarker-driven therapies to cancer patients and improve access to genomic-based medicine. ArcherDX, a molecular technology company, will provide companion diagnostic solutions from both tissue and blood-based specimens. Ayala Pharmaceuticals, a precision oncology company, is developing targeted therapies for genetically defined cancers. The collaboration will support Ayala in their pursuit of precision oncology treatment options.","partners":"Ayala Pharmaceuticals","customers":null,"investors":null,"confidence":9,"key_topics":["companion diagnostic tests","precision oncology","biomarker-driven therapies","genetic mutation detection","Notch activating mutations"],"date_of_event":"July 8, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NODVphvbxhkWZ1Yy7kBnk87dFv7C2BBzIFsz3yWqIZbIAoZEfnRgLS","news_summary":"ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4d9cf9ee-4465-4654-9169-19de901f1ff0","date":"May 28, 2019","link":"https://en.globes.co.il/en/article-cancer-drug-developer-ayala-pharmaceuticals-raises-30m-1001287530","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Investment, Clinical Trials","company":"Ayala Pharmaceuticals Inc.","layoffs":"Not mentioned","summary":"Ayala Pharmaceuticals Inc., an Israeli clinical-stage company developing medicines for genetically defined cancers, has completed a $30 million Series B financing round. The investment was led by Novartis and included participation from SBI JI Innovation Fund and all existing investors. The funds will be used for the clinical development of AL101, a pan-Notch inhibitor currently being evaluated for adenoid cystic carcinoma (ACC). The company also plans to initiate a Phase II clinical trial in triple negative breast cancer (TNBC).","partners":"Novartis","customers":"Not mentioned","investors":["Novartis","SBI JI Innovation Fund","Israel Biotech Fund","aMoon","Harel Insurance Investments and Financial Services Ltd."],"confidence":9,"key_topics":["Series B Financing","Cancer Treatment","Clinical Trials","Investment","Drug Development"],"date_of_event":"May 28, 2019","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$30 million","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LTtd8pu72eevnFrmuqrOM1hybcznikbRtc0XDHAnI0IustsYU9lN0X","news_summary":"Cancer drug developer Ayala Pharmaceuticals raises $30m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"e96cd00e-1744-43f0-9ffd-f19d9113e28a","date":"May 24, 2019","link":"https://www.businesswire.com/news/home/20190611005617/en/Ayala-Pharmaceuticals-Present-Raymond-James-Life-Sciences","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ex7RIyAqzWRs3fK0ynqlYj9EktcLmFN67CyHTGV0Hhh1xbL2AohRRj","news_summary":"Ayala Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ee6377fa-70af-4d97-818c-228e4ab39814","date":"May 20, 2019","link":"https://apnews.com/Business%20Wire/0fba61f459ed4db8ab5a2f96f5ce062b","source":"apnews.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"8N9yFwmoBoq6HwlFo4ZOVrvvBstBORoigHaKtlEP9eRUskOsYkcfV6","news_summary":"Ayala Pharmaceuticals to Present at ASCO Annual Meeting on Investigational Drug AL101 in Adenoid Cystic Carcinoma and Triple Negative Breast Cancer","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"5b147518-1ce8-47e3-b8fd-23d9364c3136","date":"May 13, 2019","link":"https://www.apnews.com/Business%20Wire/dd72ce1326f04431b2908a14976e9485","source":"www.apnews.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ZnoQuJbFnMUOomUwoKM1KEbS8zXqhaMfMYK9jkne0xpbHI7Wx9dEfG","news_summary":"FDA Grants Orphan Drug Designation to Ayala's AL101 for Potential Treatment of Adenoid Cystic Carcinoma (ACC)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d3d97189-721c-41fe-9576-ab2e5da568a2","date":"Mar 6, 2019","link":"https://www.apnews.com/Business%20Wire/eae9642bf74d4ab3bbac3f2224fe2d3a","source":"www.apnews.com","visible":1,"analysis":{"tags":"clinical-stage company","company":"Ayala Pharmaceuticals, Inc.","layoffs":null,"summary":"Ayala Pharmaceuticals, Inc. will present new data for AL101, a potential therapy for adenoid cystic carcinoma (ACC) with Notch activating mutations, at the 2019 American Association for Cancer Research (AACR) Annual Meeting. The data shows that AL101 has a significant effect on tumor growth inhibition in ACC patient-derived xenograft (PDX) tumors with Notch activating mutations. These results support the clinical development of AL101 as a targeted monotherapy for ACC tumors with Notch activating mutations. Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies for genetically defined cancers.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["AL101","Notch activating mutations","ACC tumors","Phase 2 clinical trial","gamma secretase inhibitor"],"date_of_event":"April 3, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"X55unNmoEhiceyBYUk3EJ9T3BL45ufJuWUMtazl7QpSpGPdmu7uplM","news_summary":"Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a8fb8bb3-17b2-4165-b8f2-5cfc44eefcfc","date":"Dec 24, 2018","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3752698,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"investment, partnership","company":"Novartis International AG","layoffs":"","summary":"Pharma multinational Novartis International AG has made a $10 million equity investment in Ayala Pharmaceuticals Inc., a clinical-stage company developing targeted therapies for genetically-defined cancers. The investment is part of a licensing option agreement between the two companies. Novartis will evaluate one of Ayalas drug candidates for the treatment of multiple myeloma, while Ayala retains licensing rights for all other indications of the drug.","partners":"Ayala Pharmaceuticals Inc.","customers":"","investors":"","confidence":8,"key_topics":["Novartis","Ayala Pharmaceuticals","equity investment","licensing option agreement","targeted therapies"],"date_of_event":"2018-12-24","valuation_amount":"","impact_on_company":"growth-positive","investment_amount":"$10 million","structured_issues":["Investment"],"acquisition_amount":"","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xHYz5aYuZDJac0YiM1OHgZOC6qw0wSuQbg12UxoPL0LaRzSfVaCRJ1","news_summary":"Novartis Invests $10 Million in Anti-Cancer Company Ayala Pharmaceuticals","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"fef9f8e9-7d81-4158-b6ba-5a2a2a808b14","date":"Dec 20, 2018","link":"https://www.marketwatch.com/press-release/ayala-pharmaceuticals-signs-deal-to-develop-and-commercialize-al102-in-combination-with-bcma-targeting-agents-in-multiple-myeloma-2018-12-20","source":"www.marketwatch.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"bQk2rT9TV5ulo2nPmVTVEAgVorI4dvEPbCY7MMeeSMKLcOq80MJwuS","news_summary":"https://www.marketwatch.com/press-release/ayala-pharmaceuticals-signs-deal-to-develop-and-commercialize-al102-in-combination-with-bcma-targeting-agents-in-multiple-myeloma-2018-12-20","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"e58a9075-3bc6-43a8-873d-7c702c58018a","date":"Dec 17, 2018","link":"https://www.marketwatch.com/press-release/ayala-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-study-of-lead-product-candidate-al101-for-adenoid-cystic-carcinoma-with-notch-activated-mutations-2018-12-17","source":"www.marketwatch.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"1gav5O9QQCLI0ZUer1HOC9y4xl4KECBEFjfxxUyc7VHPBYhOztmpJi","news_summary":"https://www.marketwatch.com/press-release/ayala-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-study-of-lead-product-candidate-al101-for-adenoid-cystic-carcinoma-with-notch-activated-mutations-2018-12-17","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"5ebaea1f-0754-479b-b0be-e59fc8e371ac","date":"Apr 11, 2018","link":"http://www.globes.co.il/en/article-cancer-drug-developer-ayala-pharmaceuticals-raises-17m-1001231474","source":"www.globes.co.il","visible":1,"analysis":{"tags":"oncology drug development","company":"Ayala Pharmaceuticals","layoffs":null,"summary":"Israeli oncology drug development company Ayala Pharmaceuticals has raised $17 million in a Series A financing round. The funds will be used for the first Phase II study in recurrence or metastatic Adnoid Cystic Carcinoma (ACC) patients with activated Notch pathway and for conducting preclinical research. Ayala Pharmaceuticals expects the results of the Phase II trial for ACC in the first half of 2019. The company is also exploring the use of the drug in treating triple-negative breast cancer.","partners":null,"customers":null,"investors":["Israel Biotech Fund","aMoon","Harel Insurance & Finance"],"confidence":9,"key_topics":["Series A financing","Phase II study","cancer treatment candidates","activated Notch pathway","rare cancer"],"date_of_event":"April 11, 2018","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$17 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0AUqxltfXYJ4q6H4mllHFZe647gqRgf1cXrWP29vnklsc9NZXgE4wy","news_summary":"Cancer drug developer Ayala Pharmaceuticals raises $17m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7593c357-c3c5-48a4-b3c4-cd134d8fe28e","date":"Dec 6, 2017","link":"https://www.businesswire.com/news/home/20171206005716/en/Ayala-Pharmaceuticals-Founded-Israel-Biotech-Fund-aMoon","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"wtvRt1GqDcPl8FnFLaSKOZsI9N5Jn8C92jgirimWUC6q6nLWJa32iL","news_summary":"Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":26,"techcommunityinvolvement":null,"mediagallery":[],"tags":["rare-diseases","cancer","genomics","cell-therapy","drug-discovery","oncology","therapeutics","pharmaceuticals","life-sciences","patients"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["BMS-986115","AL102","AL101","BMS-906024"],"geomarkets":["United States"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":6,"lastfunding":"$55M","totalrounds":5,"fundingstage":"Acquired","totalfunding":"$102M","publicinvestors":6,"lastpublicfunding":55000000,"totalpublicrounds":5,"totalpublicfunding":102000000},"team":[{"name":"Ken  Berlin","email":"ken.b@ayalapharma.com","phone":"","gender":"Male","userid":"v7ejuXgECzwIAbkhDRl9i24ue25zpv9iSMn8otIRyy3K9l77x17wDv","bounced":false,"claimed":null,"founder":0,"urlname":"ken-berlin-2","visible":1,"memberid":"ktedB3EpaJF9x5XGZb5A2alTHPpEK34uaZCdHhw6HSY07961al22s1","position":"President & CEO","last_name":"Berlin","claimtoken":"MG2bppRB2x60LwnqodAjzCj5ZajjyVvpuMPZe5dvuAbpAqe4zigtKW","first_name":"Ken ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/kenberlin/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2024-01-04 15:06:18.000000","initials":"KB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Dana Gelbaum","email":"dana.g@ayalapharma.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoLqNjcoIDA","bounced":false,"claimed":0,"founder":0,"urlname":"dana-gelbaum-3","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg-viUnwoM","position":"CBO","last_name":"Gelbaum","claimtoken":"MIjZ0TAZJ5EDBhww1EWUeNgw7Li0Yt1WIlfZ4h57UkOmX0XwtyYd86","first_name":"Dana","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/dana-gelbaum-051a6618/","unsubscribed":false,"is_activeuser":1,"additionalemail":"dana.gelbaum@gmail.com","claimedemaildate":"2024-01-04 15:06:39.000000","initials":"DG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"David Caron","email":"david.c@ayalapharma.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4OTPzKUJDA","bounced":false,"claimed":0,"founder":0,"urlname":"david-caron","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg5IGnuQsM","position":"VP CMC","last_name":"Caron","claimtoken":"CpMw4IjpIHcyCficU7aT1rIseCrO5VqEdO7REgmrwXcKq7YVVoaOEk","first_name":"David","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/david-caron-ba12098/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-01-04 15:06:41.000000","initials":"DC","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Irit Klipper-Avni","email":"irit.k@ayalapharma.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Nit5pEKDA","bounced":false,"claimed":0,"founder":0,"urlname":"irit-klipper-avni","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgpOiUpwoM","position":"VP HR","last_name":"Klipper-Avni","claimtoken":"9RFAORdqWYlju2UOfRTTCVHZlTLJgRtvdCwxdPcs4BVh0KKGkQ7Rkw","first_name":"Irit","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/irit-klipper-avni/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-01-04 15:06:44.000000","initials":"IK","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMGgoMMJDA","fullname":"Yanina Wainscheinker"},"biverifydate":"2020-05-10T00:00:00.000Z","crunchbaseid":"ayala-pharmaceuticals","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Natalia Golczar","creator_email":"ngolczar@gmail.com","createdate":"2017-12-19T00:00:00.000Z","biverification":"Yanina Wainscheinker","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"9GrEIhMDuXgI8iLDgHYdq9npcHP8nXdLMGmw1v2DAT6GAO0uAI66Vl","date":"May 2024","amount":"Undisclosed","source":"https://ir.ayalapharma.com/news-releases/news-release-details/ayala-pharmaceuticals-files-form-15-voluntarily-deregister-and","ticker":null,"eventtype":"DelistingEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"OTC","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCI2oTbCgw","stockexchange_logokey":"$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","exit_label":"","po_label":"Public Offering","duetoacquisition":"","isdelisting":1,"acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"cnc2Kqo8Xks4U4OQtidB0qAHFTKZO5efTYcpaJScpvOhyM9yRPg72d","date":"Oct 2023","amount":"Undisclosed","source":"https://finance.yahoo.com/news/ayala-pharmaceuticals-announces-closing-merger-120000486.html","ticker":"ADXS","eventtype":"ReverseMergerEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"OTC","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCI2oTbCgw","stockexchange_logokey":"$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","acquiredcompany_reverse":"BioSight","acquiredcompany_reverse_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6Y9LoLDA","acquiredcompany_reverse_type":"Startup","acquiredcompany_reverse_hidden":false,"acquiredcompany_reverse_fullurl":"/company_page/biosight","acquiredcompany_reverse_logokey":"$SqyTguoYN862q8mFdZlPDLGotRL76WAcHPB1YM5V7Ecl4cRSyZLcJu","acquiredcompany_reverse_urlname":"/company_page/biosight","acquiredcompany_reverse_homepage":"","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","acquiredcompany_reverse_logourl":"https://storage.googleapis.com/clean-finder-353810/$SqyTguoYN862q8mFdZlPDLGotRL76WAcHPB1YM5V7Ecl4cRSyZLcJu","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"Je7gUzsBzBWLSYmJFmJeKMNyca5vPCyRmJwskLL7Eb9VsNcW45rIvl","date":"Oct 2023","amount":"Undisclosed","source":"https://www.themiddlemarket.com/latest-news/ayala-pharmaceuticals-merges-with-biosight","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"acquiredcompany_mna":"BioSight","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6Y9LoLDA","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/biosight","acquiredcompany_mna_logokey":"$SqyTguoYN862q8mFdZlPDLGotRL76WAcHPB1YM5V7Ecl4cRSyZLcJu","acquiredcompany_mna_urlname":"/company_page/biosight","acquiredcompany_mna_homepage":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$SqyTguoYN862q8mFdZlPDLGotRL76WAcHPB1YM5V7Ecl4cRSyZLcJu","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"rmmBWq1hAyGylw3w0MRZgpJRHjLWDJwEByp2bP1NreGAGYlAQlrWx2","date":"Jan 2023","amount":"Undisclosed","source":"https://www.globenewswire.com/news-release/2023/01/19/2591928/0/en/Advaxis-and-Ayala-Pharmaceuticals-Complete-Merger.html#:~:textJanuary%2019%2C%202023%2009%3A37,%7C%20Source%3A%20Advaxis%2C%20Inc.","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Advaxis","acquiredcompany_mna_id":"G3KQrnvgade2gVBgolHAutDxHMbSIuC2XMmIor6vYfaWryRQdnwIx1","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/advaxis","acquiredcompany_mna_logokey":"$gJx7zln3CpWBdgNL1NyuVFPgXPgypC7Z0IPs2dC3gDNnrtnqU1yxQA","acquiredcompany_mna_urlname":"/company_page/advaxis","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$gJx7zln3CpWBdgNL1NyuVFPgXPgypC7Z0IPs2dC3gDNnrtnqU1yxQA","exit_label":"","po_label":"Public Offering","acquireddesc":"Merged to","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"wlHTEqJF2RrlnMhNntjqUJK8w1lO5QMDU0itBDcITSiYwPosNKW1JQ","date":"Nov 2022","amount":"Undisclosed","source":"https://ayalapharma.gcs-web.com/news-releases/news-release-details/ayala-pharmaceuticals-reports-third-quarter-2022-financial","ticker":null,"eventtype":"DelistingEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","duetoacquisition":"","isdelisting":1,"acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCu4-elCAw","date":"May 2020","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-ayala-pharmaceuticals-raises-55m-in-nasdaq-ipo-1001328011, https://www.nasdaq.com/articles/ayala-pharmaceuticals-inc.-ayla-reports-q1-loss-misses-revenue-estimates","ticker":"AYLA","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$55M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":55000000,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCUz_rHCgw","date":"May 2019","amount":"$30M","source":"https://en.globes.co.il/en/article-cancer-drug-developer-ayala-pharmaceuticals-raises-30m-1001287530","eventtype":"FundingRoundEvent","investment":[{"name":"Novartis","type":"Multinational","amount":0,"hidden":false,"country":"Switzerland","fullurl":"/mnc_page/novartis","logokey":"$gW7PSLAePTQhiSWUj7HtrrXeQA59dYiW46Lu5CsXflDlheYhHYIhIi","tagline":"Pharmaceuticals","urlname":"/mnc_page/novartis","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwOjC0J4JDA","fundingtype":"Multinational","leadpartner":null,"investmentid":"00UZYnfs7fXFz55ijho4ZyZ7q87fERkoNUnVIxUjLK7jKQ3ukFtsgL","fundingsubtype":"","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$gW7PSLAePTQhiSWUj7HtrrXeQA59dYiW46Lu5CsXflDlheYhHYIhIi","leadcaption":"Lead ","followupcaption":""},{"name":"Shavit Capital Fund","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/shavit-capital-fund","logokey":"$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","tagline":null,"urlname":"/investor_page/shavit-capital-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNG_lJEKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"FjVID7Aioc08fa3Xe3dCVis62qCU1iR4beqe50k4yaRuixGPBAYeJN","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","leadcaption":"","followupcaption":""},{"name":"Harel Insurance & Finance","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/harel-insurance-finance","logokey":"$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","tagline":null,"urlname":"/investor_page/harel-insurance-finance","isisraeli":1,"investorid":"7IA52i2eTfWfJysCrQqMc9KYgUk2NiYwEDYRYWntmIvgUwfrOmjt2F","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"UFyp18UfrkSTCgozSkB6cGoBFxQfu0eEpCNE9jEhdXeAV93Cnigv1Z","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","leadcaption":"","followupcaption":"Follow on "},{"name":"Israel Biotech Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"dUsWP6URdX2YrYjF6g7QeUVXUChvPeKGZ1RTmEpAXHbEMK3MrQskw3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"","followupcaption":"Follow on "},{"name":"SBI JI Innovation Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/sbi-ji-innovation-fund","logokey":"$l5XLL7u3lPaEq6FIDtyqX4jY9ExGEQDE2YB5yvBXJ3j9wNR3iQzAyK","tagline":null,"urlname":"/investor_page/sbi-ji-innovation-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJvW_-EKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"pVYlkJ8YjcIw40OPzAkQ6O5TXeRJw3V2yDMgCpLvqeiXv7Lio90LAi","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$l5XLL7u3lPaEq6FIDtyqX4jY9ExGEQDE2YB5yvBXJ3j9wNR3iQzAyK","leadcaption":"","followupcaption":""},{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"re6WqXxVjOUo87Fx68SVhm0zMPMOVP8mI0VqUvXpr3A7prARz0LlzS","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":30000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEyJneCgw","date":"Apr 2018","amount":"$17M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Israel Biotech Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"6310963a-d410-45be-b207-bb84910edce7","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"","followupcaption":""},{"name":"Harel Insurance & Finance","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/harel-insurance-finance","logokey":"$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","tagline":null,"urlname":"/investor_page/harel-insurance-finance","isisraeli":1,"investorid":"7IA52i2eTfWfJysCrQqMc9KYgUk2NiYwEDYRYWntmIvgUwfrOmjt2F","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bzQ8agtZuSdapyF0S911DZSMYW9gNXbwGQD5mq3zr9yzNRSAdWHTGu","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","leadcaption":"","followupcaption":""},{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"f0e6be79-4bb1-4141-ae3c-1c46f90e619b","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":17000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEvIyPCQw","date":"Dec 2017","amount":"Undisclosed","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"Bristol-Myers Squibb (BMS) ","type":"Investor","amount":0,"hidden":true,"country":"US","fullurl":"/investor_page/bristol-myers-squibb-bms","logokey":null,"tagline":"","urlname":"/investor_page/bristol-myers-squibb-bms","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODk_JPmCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"5538f650-7182-425b-a82a-ca7a0018166c","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":1,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":0,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk8IGSCgw","date":"Dec 2017","amount":"Undisclosed","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0dd75aa0-4e72-4803-978e-baaf77f67f9a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":"Follow on "},{"name":"Israel Biotech Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"23ae32b2-a008-429e-88f4-a0eb175bb30c","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"","followupcaption":"Follow on "},{"name":"Harel Insurance & Finance","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/harel-insurance-finance","logokey":"$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","tagline":null,"urlname":"/investor_page/harel-insurance-finance","isisraeli":1,"investorid":"7IA52i2eTfWfJysCrQqMc9KYgUk2NiYwEDYRYWntmIvgUwfrOmjt2F","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4zdHLOOFuG0jSntvSDGhaH72lSHIJzNzWzdv0ndnQQnmfCPAt60v1W","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"1/2017","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Ayala Pharmaceuticals","logourl":"https://storage.googleapis.com/clean-finder-353810/$3qXch2p2aevQd2Qmpo1H1HSUsFRdIUDzmD1E4Kauj00mt7A5Pc2bl9","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$3qXch2p2aevQd2Qmpo1H1HSUsFRdIUDzmD1E4Kauj00mt7A5Pc2bl9","seoabout":"Ayala Pharmaceuticals is a clinical-stage precision oncology company dedicated to developing and commercializing potential small molecule therapeutics for ...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":4,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Cells#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Cells","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Cells"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Cells","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7vMIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Cells"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"9GrEIhMDuXgI8iLDgHYdq9npcHP8nXdLMGmw1v2DAT6GAO0uAI66Vl","date":"May 2024","amount":"Undisclosed","source":"https://ir.ayalapharma.com/news-releases/news-release-details/ayala-pharmaceuticals-files-form-15-voluntarily-deregister-and","ticker":null,"eventtype":"DelistingEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"OTC","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCI2oTbCgw","stockexchange_logokey":"$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","exit_label":"","po_label":"Public Offering","duetoacquisition":"","isdelisting":1,"acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"cnc2Kqo8Xks4U4OQtidB0qAHFTKZO5efTYcpaJScpvOhyM9yRPg72d","date":"Oct 2023","amount":"Undisclosed","source":"https://finance.yahoo.com/news/ayala-pharmaceuticals-announces-closing-merger-120000486.html","ticker":"ADXS","eventtype":"ReverseMergerEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"OTC","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCI2oTbCgw","stockexchange_logokey":"$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","acquiredcompany_reverse":"BioSight","acquiredcompany_reverse_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6Y9LoLDA","acquiredcompany_reverse_type":"Startup","acquiredcompany_reverse_hidden":false,"acquiredcompany_reverse_fullurl":"/company_page/biosight","acquiredcompany_reverse_logokey":"$SqyTguoYN862q8mFdZlPDLGotRL76WAcHPB1YM5V7Ecl4cRSyZLcJu","acquiredcompany_reverse_urlname":"/company_page/biosight","acquiredcompany_reverse_homepage":"","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$l5ZX9YNy6Cv2J011ATQOiMvna2fqNmZF72OxA34HwNaoBY1LKosRTE","acquiredcompany_reverse_logourl":"https://storage.googleapis.com/clean-finder-353810/$SqyTguoYN862q8mFdZlPDLGotRL76WAcHPB1YM5V7Ecl4cRSyZLcJu","exit_label":"","po_label":"Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"rmmBWq1hAyGylw3w0MRZgpJRHjLWDJwEByp2bP1NreGAGYlAQlrWx2","date":"Jan 2023","amount":"Undisclosed","source":"https://www.globenewswire.com/news-release/2023/01/19/2591928/0/en/Advaxis-and-Ayala-Pharmaceuticals-Complete-Merger.html#:~:textJanuary%2019%2C%202023%2009%3A37,%7C%20Source%3A%20Advaxis%2C%20Inc.","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Advaxis","acquiredcompany_mna_id":"G3KQrnvgade2gVBgolHAutDxHMbSIuC2XMmIor6vYfaWryRQdnwIx1","acquiredcompany_mna_type":"Company","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/company_page/advaxis","acquiredcompany_mna_logokey":"$gJx7zln3CpWBdgNL1NyuVFPgXPgypC7Z0IPs2dC3gDNnrtnqU1yxQA","acquiredcompany_mna_urlname":"/company_page/advaxis","acquiredcompany_mna_homepage":null,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$gJx7zln3CpWBdgNL1NyuVFPgXPgypC7Z0IPs2dC3gDNnrtnqU1yxQA","exit_label":"","po_label":"Public Offering","acquireddesc":"Merged to","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"wlHTEqJF2RrlnMhNntjqUJK8w1lO5QMDU0itBDcITSiYwPosNKW1JQ","date":"Nov 2022","amount":"Undisclosed","source":"https://ayalapharma.gcs-web.com/news-releases/news-release-details/ayala-pharmaceuticals-reports-third-quarter-2022-financial","ticker":null,"eventtype":"DelistingEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"","po_label":"Public Offering","duetoacquisition":"","isdelisting":1,"acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCu4-elCAw","date":"May 2020","amount":"Undisclosed","source":"https://en.globes.co.il/en/article-ayala-pharmaceuticals-raises-55m-in-nasdaq-ipo-1001328011, https://www.nasdaq.com/articles/ayala-pharmaceuticals-inc.-ayla-reports-q1-loss-misses-revenue-estimates","ticker":"AYLA","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"$55M","stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":55000000,"valuationnumber":null}],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCUz_rHCgw","date":"May 2019","amount":"$30M","source":"https://en.globes.co.il/en/article-cancer-drug-developer-ayala-pharmaceuticals-raises-30m-1001287530","eventtype":"FundingRoundEvent","investment":[{"name":"Novartis","type":"Multinational","amount":0,"hidden":false,"country":"Switzerland","fullurl":"/mnc_page/novartis","logokey":"$gW7PSLAePTQhiSWUj7HtrrXeQA59dYiW46Lu5CsXflDlheYhHYIhIi","tagline":"Pharmaceuticals","urlname":"/mnc_page/novartis","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwOjC0J4JDA","fundingtype":"Multinational","leadpartner":null,"investmentid":"00UZYnfs7fXFz55ijho4ZyZ7q87fERkoNUnVIxUjLK7jKQ3ukFtsgL","fundingsubtype":"","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$gW7PSLAePTQhiSWUj7HtrrXeQA59dYiW46Lu5CsXflDlheYhHYIhIi","leadcaption":"Lead ","followupcaption":""},{"name":"Shavit Capital Fund","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/shavit-capital-fund","logokey":"$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","tagline":null,"urlname":"/investor_page/shavit-capital-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgNG_lJEKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"FjVID7Aioc08fa3Xe3dCVis62qCU1iR4beqe50k4yaRuixGPBAYeJN","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$vA62KRr8oAhlRh6QpynFhpg7usvk9m5bS7RnGX6t7fqsS2w1MGMsD9","leadcaption":"","followupcaption":""},{"name":"Harel Insurance & Finance","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/harel-insurance-finance","logokey":"$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","tagline":null,"urlname":"/investor_page/harel-insurance-finance","isisraeli":1,"investorid":"7IA52i2eTfWfJysCrQqMc9KYgUk2NiYwEDYRYWntmIvgUwfrOmjt2F","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"UFyp18UfrkSTCgozSkB6cGoBFxQfu0eEpCNE9jEhdXeAV93Cnigv1Z","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","leadcaption":"","followupcaption":"Follow on "},{"name":"Israel Biotech Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"dUsWP6URdX2YrYjF6g7QeUVXUChvPeKGZ1RTmEpAXHbEMK3MrQskw3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"","followupcaption":"Follow on "},{"name":"SBI JI Innovation Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/sbi-ji-innovation-fund","logokey":"$l5XLL7u3lPaEq6FIDtyqX4jY9ExGEQDE2YB5yvBXJ3j9wNR3iQzAyK","tagline":null,"urlname":"/investor_page/sbi-ji-innovation-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoJvW_-EKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"pVYlkJ8YjcIw40OPzAkQ6O5TXeRJw3V2yDMgCpLvqeiXv7Lio90LAi","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$l5XLL7u3lPaEq6FIDtyqX4jY9ExGEQDE2YB5yvBXJ3j9wNR3iQzAyK","leadcaption":"","followupcaption":""},{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"re6WqXxVjOUo87Fx68SVhm0zMPMOVP8mI0VqUvXpr3A7prARz0LlzS","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":30000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEyJneCgw","date":"Apr 2018","amount":"$17M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Israel Biotech Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"6310963a-d410-45be-b207-bb84910edce7","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"","followupcaption":""},{"name":"Harel Insurance & Finance","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/harel-insurance-finance","logokey":"$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","tagline":null,"urlname":"/investor_page/harel-insurance-finance","isisraeli":1,"investorid":"7IA52i2eTfWfJysCrQqMc9KYgUk2NiYwEDYRYWntmIvgUwfrOmjt2F","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bzQ8agtZuSdapyF0S911DZSMYW9gNXbwGQD5mq3zr9yzNRSAdWHTGu","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","leadcaption":"","followupcaption":""},{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"f0e6be79-4bb1-4141-ae3c-1c46f90e619b","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":17000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCk8IGSCgw","date":"Dec 2017","amount":"Undisclosed","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"aMoon Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/amoon-partners","logokey":"$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","tagline":null,"urlname":"/investor_page/amoon-partners","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIj37p8KDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0dd75aa0-4e72-4803-978e-baaf77f67f9a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$XFAsLr4oM0cpGPl8KooBiRDedzqYg8XejD5EGeDP9vLvSOQjBic7lH","leadcaption":"","followupcaption":"Follow on "},{"name":"Israel Biotech Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"23ae32b2-a008-429e-88f4-a0eb175bb30c","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"","followupcaption":"Follow on "},{"name":"Harel Insurance & Finance","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/harel-insurance-finance","logokey":"$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","tagline":null,"urlname":"/investor_page/harel-insurance-finance","isisraeli":1,"investorid":"7IA52i2eTfWfJysCrQqMc9KYgUk2NiYwEDYRYWntmIvgUwfrOmjt2F","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"4zdHLOOFuG0jSntvSDGhaH72lSHIJzNzWzdv0ndnQQnmfCPAt60v1W","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$eer3trCbMymhkw74aHRrv9S0RWCWy2WY5QqJwAgg20sbhhQTXZrk0k","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEvIyPCQw","date":"Dec 2017","amount":"Undisclosed","source":"Added by Daniela Gehtaman","eventtype":"GrantEvent","granttype":0,"investment":[{"name":"Bristol-Myers Squibb (BMS) ","type":"Investor","amount":0,"hidden":true,"country":"US","fullurl":"/investor_page/bristol-myers-squibb-bms","logokey":null,"tagline":"","urlname":"/investor_page/bristol-myers-squibb-bms","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODk_JPmCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"5538f650-7182-425b-a82a-ca7a0018166c","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":null,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":1,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":0,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[{"id":"Je7gUzsBzBWLSYmJFmJeKMNyca5vPCyRmJwskLL7Eb9VsNcW45rIvl","date":"Oct 2023","amount":"Undisclosed","source":"https://www.themiddlemarket.com/latest-news/ayala-pharmaceuticals-merges-with-biosight","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":0,"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"acquiredcompany_mna":"BioSight","acquiredcompany_mna_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6Y9LoLDA","acquiredcompany_mna_type":"Startup","acquiredcompany_mna_hidden":false,"acquiredcompany_mna_fullurl":"/company_page/biosight","acquiredcompany_mna_logokey":"$SqyTguoYN862q8mFdZlPDLGotRL76WAcHPB1YM5V7Ecl4cRSyZLcJu","acquiredcompany_mna_urlname":"/company_page/biosight","acquiredcompany_mna_homepage":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$SqyTguoYN862q8mFdZlPDLGotRL76WAcHPB1YM5V7Ecl4cRSyZLcJu","exit_label":"","po_label":"Public Offering","acquireddesc":"Acquired","sectionname":"Merger & Acquisitions","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"others":[]}}